The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillips, J. M.
Right arrow Articles by Cooke, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, J. M.
Right arrow Articles by Cooke, A.
The Journal of Immunology, 00, 165: 1949-1955.
Copyright © 00 by The American Association of Immunologists

Nondepleting Anti-CD4 Has an Immediate Action on Diabetogenic Effector Cells, Halting Their Destruction of Pancreatic ß Cells1

Jenny M. Phillips2,*, Silvia Zusman Harach*, Nicole M. Parish*, Zoltan Fehervari*, Katherine Haskins{dagger} and Anne Cooke*

* Department of Pathology, University of Cambridge, Cambridge, United Kingdom; and {dagger} Department of Immunology, University of Colorado Health Sciences Center, Denver, CO 80262

The induction of tolerance in a primed immune system is a major aim for therapy in autoimmunity and transplant rejection. In this paper, we investigate the action of the nondepleting anti-CD4 Ab, YTS 177. Although this Ab is nondepleting, we have demonstrated a direct action in vivo on activated effector cells. We show that the Ab inhibits transfer of insulin-dependent diabetes mellitus by the CD4+ Th1 clone BDC2.5 to nonobese diabetic mice. Furthermore, we show that this Ab acts directly on diabetogenic effector cells because it prevented BDC2.5-induced insulin-dependent diabetes mellitus in nonobese diabetic-scid recipients in the absence of other T cells. The Ab halts the diabetic process even when it is administered after the BDC2.5 cells have infiltrated the pancreas and destruction of islets is already underway. This is accompanied by an immediate decrease in proinflammatory cytokine production with cessation of ß cell destruction and disappearance of infiltrating cells from the pancreas, leaving any remaining ß cells intact. These data suggest that Abs such as this may be effective not only because they induce regulatory T cells but also because they are able to directly prevent effector cell function.




This article has been cited by other articles:


Home page
DiabetesHome page
J. M. Phillips, L. O'Reilly, C. Bland, A. K. Foulis, and A. Cooke
Patients With Chronic Pancreatitis Have Islet Progenitor Cells in Their Ducts, but Reversal of Overt Diabetes in NOD Mice by Anti-CD3 Shows No Evidence for Islet Regeneration
Diabetes, March 1, 2007; 56(3): 634 - 640.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Winsor-Hines, C. Merrill, M. O'Mahony, P. E. Rao, S. P. Cobbold, H. Waldmann, D. J. Ringler, and P. D. Ponath
Induction of Immunological Tolerance/Hyporesponsiveness in Baboons with a Nondepleting CD4 Antibody
J. Immunol., October 1, 2004; 173(7): 4715 - 4723.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Rabinovitch, W. L. Suarez-Pinzon, A.M. J. Shapiro, R. V. Rajotte, and R. Power
Combination Therapy With Sirolimus and Interleukin-2 Prevents Spontaneous and Recurrent Autoimmune Diabetes in NOD Mice
Diabetes, March 1, 2002; 51(3): 638 - 645.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.